Both eszopiclone and sustained-release zolpidem are effective for both sleep-onset and sleep-maintenance insomnia, with a reduced abuse potential and long-term efficacy of up to 6 months as compared with nonselective benzodiazepine receptor agonists.
It is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
Ramelteon is a melatonin receptor agonist that is indicated for insomnia characterized by difficulty with sleep onset.
This agent has high selectivity for human melatonin MT1 and MT2 receptors.
A second dose can be used during the middle of the night without residual sedation in the morning (this is believed to be an advantage of this hypnotic over others).
A sedative-hypnotic of the imidazopyridine class, zolpidem has a rapid onset and short duration of action.